Retatrutide is fundamentally different
Transition to Branded Medications : Begin prescribing Wegovy or Ozempic, ensuring prescribers are trained on eligibility criteria (e.g., BMI thresholds)
Conclusion GLP-1 therapies have shown promise in improving heart health and supporting weight loss, with major trials highlighting their ability to reduce key cardiovascular events across a variety of patient groups
Haufe S, Kaminski J, Utz W, Haas V, Mhler A, Daniels MA, et al
(You can also look up larger outsourcing facilities to be sure theyre registered with the FDA.) So whats the current status of compounded GLP-1s, and are they all going to go off the market
24 They are prescribed for type 2 diabetes mellitus (T2DM) and obesity, for which they currently have approval from the United States (US) Food and Drug Administration (FDA)